| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | President, R&D, and CMO | Chief Medical Officer, EVP R&D
1 company
Taub Rebecca is a Director at MDGL. Recent filings cover 0 purchases and 92 sales.
Our model assigns Taub Rebecca a below-average insider score of 36/100, based on 14 past trades. Over a 12-month horizon, 0.0% of those trades were profitable, with an average 12-month return of -46.1%.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jan 17, 2025 | MDGL Madrigal Pharmaceuticals, Inc. | President, R&D, and CMO | Sell | 1,689 | $273.41 | $461,789.49 | -0.4% | +2.7% | +70.8% | |
| Apr 8, 2024 | MDGL Madrigal Pharmaceuticals, Inc. | President, R&D, and CMO | Sale+OE10b5-1 | 2,676 | $245.99 | $658,257.61 | -0.6% | +16.9% | +21.8% | |
| Apr 5, 2024 | MDGL Madrigal Pharmaceuticals, Inc. | President, R&D, and CMO | Sale+OE10b5-1 | 73,888 | $243.92 | $18,022,588.47 | -13.9% | +13.8% | +29.4% | |
| Jun 11, 2018 | MDGL Madrigal Pharmaceuticals, Inc. | Chief Medical Officer, EVP R&D | Sell | 73,526 | $287.46 | $21,135,783.96 | -10.1% | - | - |